<p>Praxis Investment Management Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在因塞特医疗（Incyte Corporation，NASDAQ:INCY - 免费报告）的股份增加了 82.2%。这家机构投资者在此期间购买了 3,150 股后，持有该生物制药公司 6,980 股股票。根据其最近的 SEC 文件，Praxis Investment Management Inc.在因塞特医疗的持股价值为 475,000 美元。</p>
<ul>
<li>因塞特医疗能否实现 447% 的每股收益预测和管道热度？</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Banque Transatlantique SA 在第一季度以 26,000 美元的估值购买了因塞特医疗的新股份。Hilltop National Bank 在第二季度购买了约 37,000 美元的因塞特医疗股份。SVB Wealth LLC 在第一季度以约 39,000 美元的估值购买了因塞特医疗的新股份。Geneos Wealth Management Inc.在第一季度将其在因塞特医疗的持股增加了 350.0%。Geneos Wealth Management Inc.现在拥有 756 股该生物制药公司的股票，价值 46,000 美元，此前在上个季度又购买了 588 股。最后，WPG Advisers LLC 在第一季度以约 47,000 美元的估值购买了因塞特医疗的新股份。96.97% 的股票由机构投资者持有。</p>
<h2>因塞特医疗的内部交易</h2>
<p>在因塞特医疗的其他消息中，执行副总裁 Steven H. Stein 于 7 月 21 日星期一出售了 3,706 股公司的股票。股票以平均价格 67.94 美元出售，总价值为 251,785.64 美元。出售完成后，该执行副总裁直接持有 102,886 股公司的股票，价值约为 6,990,074.84 美元。这代表其持股减少了 3.48%。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。在过去的九十天里，内部人士已出售 4,261 股公司股票，价值 298,482 美元。公司内部人士持有 17.80% 的公司股票。</p>
<h2>华尔街分析师的看法</h2>
<ul>
<li>2024 年盈利增长的五大医疗股</li>
</ul>
<p>几位股票研究分析师最近对 INCY 股票发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对因塞特医疗股票的 “持有（c+）” 评级。美国银行在 9 月 4 日的研究报告中将因塞特医疗股票的目标价格从 90.00 美元提高到 104.00 美元，并给予该股票 “买入” 评级。巴克莱在 8 月 1 日的研究报告中开始覆盖因塞特医疗股票。他们为该公司设定了 “增持” 评级和 90.00 美元的目标价格。富国银行在 8 月 6 日的研究报告中将因塞特医疗股票的评级从 “持平” 提升至 “增持”，并将该股票的目标价格从 67.00 美元提高到 89.00 美元。最后，Truist Financial 在 7 月 30 日的研究报告中将因塞特医疗股票的目标价格从 73.00 美元提高到 79.00 美元，并给予该股票 “持有” 评级。一位股票研究分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，十二位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，因塞特医疗目前的平均评级为 “持有”，平均目标价格为 84.79 美元。</p>
<p><strong>查看我们最新的因塞特医疗股票报告</strong></p>
<h2>因塞特医疗股票上涨 0.3%</h2>
<ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
<p>因塞特医疗的 INCY 股票在周五开盘价为 87.57 美元。因塞特医疗的 52 周低点为 53.56 美元，52 周高点为 92.86 美元。该公司的债务与股本比率为 0.01，速动比率为 2.78，流动比率为 2.85。该公司的 50 日简单移动平均为 85.20 美元，200 日简单移动平均为 72.54 美元。该公司的市值为 171 亿美元，市盈率为 19.90，PEG 比率为 0.68，贝塔值为 0.73。</p>
<h2>因塞特医疗简介</h2>
<p>（免费报告）</p>
<p>因塞特医疗公司是一家生物制药公司，专注于血液学/肿瘤学、炎症和自身免疫领域的治疗药物的发现、开发和商业化。该公司提供 JAKAFI（ruxolitinib）用于治疗中度或高风险的骨髓纤维化、真性红细胞增多症和类固醇耐药性急性移植物抗宿主病；MONJUVI（tafasitamab-cxix）/MINJUVI（tafasitamab）用于复发或难治性弥漫性大 B 细胞淋巴瘤；PEMAZYRE（pemigatinib），一种成纤维细胞生长因子受体激酶抑制剂，作为液体和实体肿瘤类型的致癌驱动因子；ICLUSIG（ponatinib）用于治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病；以及 OPZELURA 乳膏用于治疗特应性皮炎。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过因塞特医疗</li>
<li>顶级生物技术股票：探索创新机会</li>
<li>强生的并购策略是投资者真正关注的故事</li>
<li>电话会议和个人投资者</li>
<li>特斯拉：一些分析师预测将下跌 30%——是时候恐慌了吗？</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>对冲基金对美元的态度转变——这三只股票的买入信号？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 INCY 股票吗？</strong> 访问 HoldingsChannel.com 获取因塞特医疗公司（NASDAQ:INCY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p>
<p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在因塞特医疗吗？</h2>
<p>在考虑因塞特医疗之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而因塞特医疗并不在名单上。</p>
<p>虽然因塞特医疗目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

因塞特医疗

<p>Praxis Investment Management Inc. 在第二季度将其在因塞特医疗的股份增加了 82.2%，额外购买了 3,150 股，使其总持股达到 6,980 股，价值 475,000 美元。其他机构投资者最近也购买了该公司的股票。因塞特医疗的股票在过去 52 周的价格范围为 53.56 美元至 92.86 美元，目前价格为 87.57 美元。分析师对该股票的评级不一，平均目标价为 84.79 美元。因塞特医疗专注于血液学/肿瘤学和炎症治疗</p>

<p>Praxis Investment Management Inc. raised its stake in Incyte Corporation (NASDAQ:INCY - Free Report) by 82.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,980 shares of the biopharmaceutical company's stock after purchasing an additional 3,150 shares during the period. Praxis Investment Management Inc.'s holdings in Incyte were worth $475,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Praxis Investment Management Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在因塞特医疗（Incyte Corporation，NASDAQ:INCY - 免费报告）的股份增加了 82.2%。这家机构投资者在此期间购买了 3,150 股后，持有该生物制药公司 6,980 股股票。根据其最近的 SEC 文件，Praxis Investment Management Inc.在因塞特医疗的持股价值为 475,000 美元。</p>
</div><ul>
<li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>因塞特医疗能否实现 447% 的每股收益预测和管道热度？</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Banque Transatlantique SA bought a new stake in Incyte in the first quarter valued at $26,000. Hilltop National Bank bought a new stake in shares of Incyte during the second quarter worth about $37,000. SVB Wealth LLC bought a new stake in shares of Incyte during the first quarter worth about $39,000. Geneos Wealth Management Inc. increased its position in shares of Incyte by 350.0% during the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company's stock worth $46,000 after acquiring an additional 588 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of Incyte during the first quarter worth about $47,000. 96.97% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Banque Transatlantique SA 在第一季度以 26,000 美元的估值购买了因塞特医疗的新股份。Hilltop National Bank 在第二季度购买了约 37,000 美元的因塞特医疗股份。SVB Wealth LLC 在第一季度以约 39,000 美元的估值购买了因塞特医疗的新股份。Geneos Wealth Management Inc.在第一季度将其在因塞特医疗的持股增加了 350.0%。Geneos Wealth Management Inc.现在拥有 756 股该生物制药公司的股票，价值 46,000 美元，此前在上个季度又购买了 588 股。最后，WPG Advisers LLC 在第一季度以约 47,000 美元的估值购买了因塞特医疗的新股份。96.97% 的股票由机构投资者持有。</p>
</div><h2>Insider Transactions at Incyte</h2>
<div class="lb-trans"><h2>因塞特医疗的内部交易</h2>
</div><p>In other Incyte news, EVP Steven H. Stein sold 3,706 shares of the company's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $67.94, for a total value of $251,785.64. Following the completion of the sale, the executive vice president directly owned 102,886 shares of the company's stock, valued at approximately $6,990,074.84. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 4,261 shares of company stock valued at $298,482. Corporate insiders own 17.80% of the company's stock.</p>
<div class="lb-trans"><p>在因塞特医疗的其他消息中，执行副总裁 Steven H. Stein 于 7 月 21 日星期一出售了 3,706 股公司的股票。股票以平均价格 67.94 美元出售，总价值为 251,785.64 美元。出售完成后，该执行副总裁直接持有 102,886 股公司的股票，价值约为 6,990,074.84 美元。这代表其持股减少了 3.48%。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。在过去的九十天里，内部人士已出售 4,261 股公司股票，价值 298,482 美元。公司内部人士持有 17.80% 的公司股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><ul>
<li>5 top healthcare stocks for earnings growth in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年盈利增长的五大医疗股</li>
</ul>
</div><p>Several equities research analysts have recently commented on INCY shares. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Incyte in a research report on Wednesday, October 8th. Bank of America boosted their target price on shares of Incyte from $90.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, September 4th. Barclays started coverage on shares of Incyte in a research report on Friday, August 1st. They set an &#34;overweight&#34; rating and a $90.00 target price for the company. Wells Fargo &amp; Company raised shares of Incyte from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and boosted their target price for the stock from $67.00 to $89.00 in a research report on Wednesday, August 6th. Finally, Truist Financial boosted their target price on shares of Incyte from $73.00 to $79.00 and gave the stock a &#34;hold&#34; rating in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Incyte currently has an average rating of &#34;Hold&#34; and an average price target of $84.79.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 INCY 股票发表了评论。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对因塞特医疗股票的 “持有（c+）” 评级。美国银行在 9 月 4 日的研究报告中将因塞特医疗股票的目标价格从 90.00 美元提高到 104.00 美元，并给予该股票 “买入” 评级。巴克莱在 8 月 1 日的研究报告中开始覆盖因塞特医疗股票。他们为该公司设定了 “增持” 评级和 90.00 美元的目标价格。富国银行在 8 月 6 日的研究报告中将因塞特医疗股票的评级从 “持平” 提升至 “增持”，并将该股票的目标价格从 67.00 美元提高到 89.00 美元。最后，Truist Financial 在 7 月 30 日的研究报告中将因塞特医疗股票的目标价格从 73.00 美元提高到 79.00 美元，并给予该股票 “持有” 评级。一位股票研究分析师对该股票给予了强烈买入评级，五位分析师给予了买入评级，十二位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，因塞特医疗目前的平均评级为 “持有”，平均目标价格为 84.79 美元。</p>
</div><p><strong>View Our Latest Stock Report on Incyte</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的因塞特医疗股票报告</strong></p>
</div><h2>Incyte Trading Up 0.3%</h2>
<div class="lb-trans"><h2>因塞特医疗股票上涨 0.3%</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>Shares of INCY stock opened at $87.57 on Friday. Incyte Corporation has a 52-week low of $53.56 and a 52-week high of $92.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.78 and a current ratio of 2.85. The company has a 50-day simple moving average of $85.20 and a two-hundred day simple moving average of $72.54. The company has a market capitalization of $17.10 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 0.68 and a beta of 0.73.</p>
<div class="lb-trans"><p>因塞特医疗的 INCY 股票在周五开盘价为 87.57 美元。因塞特医疗的 52 周低点为 53.56 美元，52 周高点为 92.86 美元。该公司的债务与股本比率为 0.01，速动比率为 2.78，流动比率为 2.85。该公司的 50 日简单移动平均为 85.20 美元，200 日简单移动平均为 72.54 美元。该公司的市值为 171 亿美元，市盈率为 19.90，PEG 比率为 0.68，贝塔值为 0.73。</p>
</div><h2>Incyte Profile</h2>
<div class="lb-trans"><h2>因塞特医疗简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.</p>
<div class="lb-trans"><p>因塞特医疗公司是一家生物制药公司，专注于血液学/肿瘤学、炎症和自身免疫领域的治疗药物的发现、开发和商业化。该公司提供 JAKAFI（ruxolitinib）用于治疗中度或高风险的骨髓纤维化、真性红细胞增多症和类固醇耐药性急性移植物抗宿主病；MONJUVI（tafasitamab-cxix）/MINJUVI（tafasitamab）用于复发或难治性弥漫性大 B 细胞淋巴瘤；PEMAZYRE（pemigatinib），一种成纤维细胞生长因子受体激酶抑制剂，作为液体和实体肿瘤类型的致癌驱动因子；ICLUSIG（ponatinib）用于治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病；以及 OPZELURA 乳膏用于治疗特应性皮炎。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Incyte</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>Conference Calls and Individual Investors</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过因塞特医疗</li>
<li>顶级生物技术股票：探索创新机会</li>
<li>强生的并购策略是投资者真正关注的故事</li>
<li>电话会议和个人投资者</li>
<li>特斯拉：一些分析师预测将下跌 30%——是时候恐慌了吗？</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>对冲基金对美元的态度转变——这三只股票的买入信号？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding INCY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 INCY 股票吗？</strong> 访问 HoldingsChannel.com 获取因塞特医疗公司（NASDAQ:INCY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Incyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在因塞特医疗吗？</h2>
</div><p>Before you consider Incyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑因塞特医疗之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而因塞特医疗并不在名单上。</p>
</div><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然因塞特医疗目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Praxis Investment Management Inc. 购入了 3,150 股因塞特医疗公司（Incyte Corporation）的股票 $INCY